<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717194</url>
  </required_header>
  <id_info>
    <org_study_id>B-2018-498-002</org_study_id>
    <nct_id>NCT03717194</nct_id>
  </id_info>
  <brief_title>Effect of Ertugliflozin on Cardiac Function in Diabetes</brief_title>
  <acronym>ERTU-GLS</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, to Evaluate the Effect of Ertugliflozin on Cardiac Function in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control and Stage B Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soo Lim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD Korea Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2
      inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using
      echocardiogram in patients with T2D and HF, who are not controlled with oral antidiabetic
      medications including DPP4 inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 3, randomized, double-blind, active-competitor, parallel-group study
      that is anticipated to enroll 120 patients. Patients taking metformin and/or DPP4 inhibitors
      as per local label for ≥12 weeks without a dose adjustment before enrollment will be eligible
      for screening. All patients will have a screening period comprised of an up to 2-week
      screening phase prior to randomization. In order to qualify for randomization, patients must
      demonstrate compliance based upon pill count (80%) and discretion of the investigators during
      the Run-in phase.

      Glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) will be masked to patients after
      randomization. To prevent partial unblinding, urinary glucose excretion (UGE) results will be
      masked to patients. Urine glucose, albumin, calcium, and creatinine will be measured
      separately on-site visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Longitudinal Strain (GLS)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of GLS after 24 weeks' treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>E/e' ratio</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of E/e' after 24 weeks' treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction (EF)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of EF after 24 weeks' treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle mass</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of LV mass after 24 weeks' treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of HbA1c mass after 24 weeks' treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of body weight mass after 24 weeks' treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat Mass</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of body fat mass after 24 weeks' treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in addition to their preexisting metformin and/or DPP4 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes</description>
    <arm_group_label>Ertugliflozin</arm_group_label>
    <other_name>Steglatro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with T2D taking oral antidiabetic medications (metformin and/or DPP4
             inhibitors) except SGLT2 inhibitors for at least 12 weeks without a dose adjustment
             before enrollment.

          -  eGFR ≥ 45 mL/min/1.73 m2.

          -  Stage B HF identified on the basis of either structural or functional markers.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  At the time of screening age &lt;20 years

          -  HbA1c &lt;7% or HbA1c &gt;9.5% at Screening

          -  FPG &gt;15 mmol/L (270 mg/dL) measured by the laboratory at Screening (Visit 1), and
             confirmed (&gt;15 mmol/L [&gt;270 mg/dL]) by a repeat test before randomization

          -  Treated with insulin and/or GLP-1R agonist within 12 weeks preceding the Screening
             Visit.

          -  Women of childbearing potential with no effective contraceptive method

          -  History of gastric surgery including history of gastric banding within 3 years before
             the Screening Visit

          -  History of diabetic ketoacidosis or nonketotic hyperosmolar coma prior to the
             Screening Visit

          -  Mean blood pressure after 3 separate measurements &gt;180 mmHg in systolic blood pressure
             (SBP) or &gt;95 mmHg in diastolic blood pressure (DBP)

          -  Patients with current or prior symptoms of HF.

          -  Patients with severe anemia, severe respiratory, hepatic, neurological, psychiatric
             disorders or active malignant tumor or other major systemic disease or patients with
             short life expectancy making implementation of the protocol or interpretation of the
             study results difficult

          -  Aspartate aminotransferase and/or alanine aminotransferase: &gt;3 times the upper limit
             of the normal laboratory range (ULN)

          -  Total bilirubin: &gt;1.5 times ULN (except in case of Gilbert's syndrome)

          -  Use of systemic glucocorticoids (excluding topical or ophthalmic, application or
             inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening
             Visit

          -  Patient who has taken other investigational drugs or prohibited therapy for this study
             within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie-Eun Lee, MD</last_name>
    <phone>+82-31-787-7815</phone>
    <email>jeleemd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soo Lim, MD, PhD</last_name>
    <phone>+82-31-787-7035</phone>
    <email>limsoo@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospita;</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Lim</last_name>
      <phone>82317877035</phone>
      <phone_ext>82317877035</phone_ext>
      <email>limsoo@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <reference>
    <citation>Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Nov 23;377(21):2099. doi: 10.1056/NEJMc1712572.</citation>
    <PMID>29166232</PMID>
  </reference>
  <reference>
    <citation>Krishnasamy R, Isbel NM, Hawley CM, Pascoe EM, Burrage M, Leano R, Haluska BA, Marwick TH, Stanton T. Left Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease. PLoS One. 2015 May 15;10(5):e0127044. doi: 10.1371/journal.pone.0127044. eCollection 2015.</citation>
    <PMID>25978372</PMID>
  </reference>
  <reference>
    <citation>Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC; American College of Cardiology; American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant. 2002 Feb;21(2):189-203.</citation>
    <PMID>11834347</PMID>
  </reference>
  <reference>
    <citation>Kosmala W, Jellis CL, Marwick TH. Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure. J Am Coll Cardiol. 2015 Jan 27;65(3):257-66. doi: 10.1016/j.jacc.2014.10.044. Epub 2014 Dec 19.</citation>
    <PMID>25533754</PMID>
  </reference>
  <reference>
    <citation>Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010 Jul 27;56(5):392-406. doi: 10.1016/j.jacc.2010.05.011.</citation>
    <PMID>20650361</PMID>
  </reference>
  <reference>
    <citation>Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986 Feb 15;57(6):450-8.</citation>
    <PMID>2936235</PMID>
  </reference>
  <reference>
    <citation>Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63.</citation>
    <PMID>16376782</PMID>
  </reference>
  <reference>
    <citation>Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009 Feb;22(2):107-33. doi: 10.1016/j.echo.2008.11.023. Review.</citation>
    <PMID>19187853</PMID>
  </reference>
  <reference>
    <citation>Reisner SA, Lysyansky P, Agmon Y, Mutlak D, Lessick J, Friedman Z. Global longitudinal strain: a novel index of left ventricular systolic function. J Am Soc Echocardiogr. 2004 Jun;17(6):630-3.</citation>
    <PMID>15163933</PMID>
  </reference>
  <reference>
    <citation>Lima MSM, Villarraga HR, Abduch MCD, Lima MF, Cruz CBBV, Sbano JCN, Voos MC, Mathias W Junior, Tsutsui JM. Global Longitudinal Strain or Left Ventricular Twist and Torsion? Which Correlates Best with Ejection Fraction? Arq Bras Cardiol. 2017 Jul;109(1):23-29. doi: 10.5935/abc.20170085. Epub 2017 Jun 29. English, Portuguese.</citation>
    <PMID>28678927</PMID>
  </reference>
  <reference>
    <citation>Medvedofsky D, Kebed K, Laffin L, Stone J, Addetia K, Lang RM, Mor-Avi V. Reproducibility and experience dependence of echocardiographic indices of left ventricular function: Side-by-side comparison of global longitudinal strain and ejection fraction. Echocardiography. 2017 Mar;34(3):365-370. doi: 10.1111/echo.13446. Epub 2017 Feb 9.</citation>
    <PMID>28185312</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>heart failure</keyword>
  <keyword>ertugliflozin</keyword>
  <keyword>Global longitudinal strain (GLS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

